Watch: the CureRays® explainer series
Prefer to read? The full guide below is complete on its own, with tables you can revisit any time.
What is plasmacytoma (solitary plasma cell tumor)?
A plasmacytoma is a tumor made up of plasma cells — a type of white blood cell that normally makes antibodies to fight infection. Unlike multiple myeloma, which is a cancer of plasma cells spread throughout the bone marrow, a plasmacytoma is a single, localized collection of these cells in one spot. There are two main forms. A solitary plasmacytoma of bone forms within a bone — often a vertebra in the spine, but also the ribs, pelvis, or other bones — and may cause pain, a weakened bone, or a fracture. An extramedullary plasmacytoma forms in soft tissue outside the bone, most often in the head and neck area such as the nasal passages, sinuses, or throat, where it may cause stuffiness, a lump, or local symptoms. Because plasmacytomas share a biology with myeloma, doctors carefully check the bone marrow and blood to confirm the disease is truly limited to one site, and they monitor over time because some plasmacytomas can later progress to multiple myeloma. The encouraging news is that plasma cells are very sensitive to radiation, so a localized plasmacytoma is usually treated — and often cured — with focused radiation therapy. Care is coordinated by a team that typically includes a radiation oncologist and a blood-cancer specialist (hematologist).
The main types
Doctors group plasmacytoma (solitary plasma cell tumor) by where it starts and how it behaves:
| Type | What it means, simply |
|---|---|
| Solitary plasmacytoma of bone | A single plasma-cell tumor within a bone, commonly a vertebra in the spine; it may cause pain or weaken the bone, and is treated mainly with radiation. |
| Extramedullary plasmacytoma | A single plasma-cell tumor in soft tissue outside the bone, most often in the head and neck (such as the sinuses or throat); it is also very responsive to radiation. |
| Plasmacytoma that progresses to myeloma | Some plasmacytomas later develop into multiple myeloma, which is why long-term monitoring of blood and marrow is an important part of care. |
Staging, in plain terms
A plasmacytoma is not staged with the TNM system used for most cancers. What matters most is confirming that it is truly solitary — a single tumor — rather than one sign of widespread multiple myeloma. To do this, doctors examine the bone marrow, run blood and urine tests for abnormal antibody proteins, and obtain whole-body imaging (such as MRI or PET scans) to make sure there are no other hidden plasma-cell tumors. If everything points to a single localized tumor with no evidence of myeloma-related organ damage, the diagnosis is a solitary plasmacytoma. Doctors also note whether any abnormal protein is present in the blood, since this can carry a higher chance of later progressing to myeloma and signals the need for closer follow-up.
| No formal TNM stage — defined by being a single, localized tumor without widespread myeloma | What it generally means |
|---|---|
| Solitary plasmacytoma | A single plasma-cell tumor with a normal bone marrow and no signs of widespread myeloma — the situation in which radiation is most often curative. |
| Solitary plasmacytoma with minimal marrow involvement | A single tumor with a small amount of abnormal plasma cells in the marrow; still treated locally but watched more closely, as the chance of later myeloma is higher. |
| Progression to multiple myeloma | When follow-up shows the disease has become widespread, treatment shifts to the systemic therapies used for multiple myeloma. |
The standard of care
Plasmacytoma (Solitary Plasma Cell Tumor) is almost always treated by a team that may include a surgeon, a medical oncologist, and a radiation oncologist, combining therapies for the best result. The usual building blocks are:
Radiation therapy
Focused radiation to the tumor is the primary and often curative treatment for plasmacytoma, because plasma cells are highly sensitive to radiation.
Surgery (in selected cases)
Surgery is sometimes used to stabilize a weakened or fractured bone, or to remove an accessible soft-tissue tumor, often alongside radiation.
Monitoring for myeloma
Regular blood tests, urine tests, and imaging track for any sign the disease is progressing to multiple myeloma, so treatment can begin promptly if needed.
Supportive care
Pain control, bone strengthening, and physical therapy help recovery, especially for plasmacytomas in the spine or weight-bearing bones.
Systemic therapy if it progresses
If the disease becomes multiple myeloma, the modern medicines used for myeloma — given by a hematologist — take the lead.
How radiation treatment works
Radiation uses focused high-energy beams to damage the DNA inside cancer cells so they can no longer grow and divide. Plasma cells — the cells that make up a plasmacytoma — are among the most radiation-sensitive cancer cells, which is exactly why radiation is the primary treatment and is frequently curative for a localized plasmacytoma. Treatment is delivered as a series of short, painless daily sessions over a few weeks, with the dose carefully shaped to cover the whole tumor while sparing nearby healthy tissue such as the spinal cord, eyes, or organs. For a plasmacytoma in a vertebra, radiation can relieve pain, control the tumor, and help protect the bone. Because some plasmacytomas can later progress to multiple myeloma, your team will continue to monitor your blood and imaging over time even after successful radiation, so that any change can be treated early. Your radiation oncologist will design a plan aimed at eliminating the tumor while protecting the structures around it.
The main ways radiation is delivered for plasmacytoma (solitary plasma cell tumor):
Targeted external-beam radiation
A precisely shaped beam delivers a curative dose to the single tumor over a series of short daily sessions, taking advantage of how sensitive plasma cells are to radiation.
Intensity-modulated radiation therapy (IMRT)
For tumors near sensitive structures — such as the spinal cord, eyes, or head and neck — IMRT shapes the dose to the tumor while sparing nearby healthy tissue.
Stereotactic body radiation therapy (SBRT)
In selected cases, highly focused radiation can treat a well-defined tumor, such as one in the spine, with steep dose fall-off to protect the spinal cord.
Latest studies shaping care
Care keeps improving — often toward getting the same excellent results with less burden on patients. A few developments:
Radiation cures many solitary plasmacytomas: Focused radiation controls the local tumor in the large majority of patients with solitary plasmacytoma and cures many outright, confirming radiation as the standard primary treatment for localized disease.[1]
Solitary plasmacytoma radiotherapy series
Predicting progression to myeloma: Research into blood markers, marrow findings, and sensitive whole-body imaging is helping identify which plasmacytomas are more likely to progress to multiple myeloma, guiding how closely each patient is followed.[2]
Plasmacytoma progression studies
Refining radiation dose: Studies are clarifying the radiation dose that reliably controls plasmacytomas while minimizing side effects, helping tailor treatment to tumor size and location.[3]
Plasmacytoma dose-response analyses
Common questions
Is a plasmacytoma the same as multiple myeloma? Not exactly. A plasmacytoma is a single, localized tumor of plasma cells, while multiple myeloma is a cancer of plasma cells spread throughout the bone marrow. They are related, and some plasmacytomas can progress to myeloma over time, which is why your team checks for myeloma at diagnosis and monitors you afterward.
Why is radiation the main treatment? Plasma cells are very sensitive to radiation. Because a plasmacytoma is concentrated in one spot, focused radiation can deliver a curative dose right to the tumor while sparing the rest of the body, making it the primary and often curative treatment for localized disease.
Will it come back or turn into myeloma? Radiation controls the local tumor in most people, and many are cured. However, because there is a chance of later developing multiple myeloma, your care team will keep monitoring your blood, urine, and imaging over time so that, if anything changes, treatment can start early.
References
Numbered sources for the studies cited above. Links open the primary publication on PubMed or the publisher’s site.